{"id":"mabcampath-1h","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets CD52, a glycoprotein expressed on B cells, T cells, and other lymphocytes. Upon binding, it triggers immune-mediated destruction of these cells, resulting in profound lymphocyte depletion. This mechanism is used therapeutically in conditions where reduction of pathogenic lymphocytes is beneficial, such as chronic lymphocytic leukemia and certain autoimmune disorders.","oneSentence":"MabCampath-1h is a humanized monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:00.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"B-cell lymphomas"}]},"trialDetails":[{"nctId":"NCT01307332","phase":"PHASE3","title":"Advanced MRI Measures of Repair in Alemtuzumab Treated Patients","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alemtuzumab"],"phase":"phase_3","status":"active","brandName":"MabCampath-1h","genericName":"MabCampath-1h","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MabCampath-1h is an antibody that inhibits the CAMPATH-1 antigen. It is being studied in a clinical trial for the treatment of Relapsing Remitting Multiple Sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}